HDAC Inhibitors
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (31 July 2011) | Viewed by 47616
Special Issue Editor
Interests: blood clotting; bleeding disorders; transfusion medics; myeloma therapy (clinical and pre-clinial)and biology; cutaneous T cell lymphoma (clinical); immunotherapy; epigenetics
Special Issue Information
Dear Colleagues,
Histone deacetylase inhibitors are clearly effective therapeutic tools in the treatment of cancers, particularly haematological malignancies. The purpose of this special issue is to provide the reader with a focused review of on the current place of HDACi as a therapy, particularly in blood cancers. We hope to provide a broad overview of the rationale behind their use, with specific papers focusing on diseases where they clearly have biological effects - NHL, Hodgkin disease, myeloid malignancies. Finally we hope to have two seperate papers examining mechanisms of resistance and common toxicities.
I hope you will be able to contribute to what I see will be a valuable compendium of insightful reviews in this very topical subject.
Prof. Dr. H. Miles Prince
Guest Editors
Keywords
- histone deacetylase
- epigenetics
- demethylation
- novel therapies
- transcription factors
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.